RT Journal Article
SR Electronic
T1 Maternal transfer of IgA and IgG SARS-CoV-2 specific antibodies transplacentally and via breastfeeding
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.21.21267733
DO 10.1101/2021.12.21.21267733
A1 Sajadi, Mohammad M.
A1 Shokatpour, Narjes
A1 Bathula, Allison
A1 Tehrani, Zahra Rikhtegaran
A1 Lankford, Allison
A1 Purcell, Madeleine
A1 Campbell, James D.
A1 Hammershaimb, Elizabeth Adrianne
A1 Deatrick, Kristopher B.
A1 Bor, Casey
A1 Parsell, Dawn M.
A1 Dugan, Colleen
A1 Levine, Andrea R.
A1 Ramelli, Sabrina C.
A1 Chertow, Daniel S.
A1 Herr, Daniel L
A1 Lewis, George K.
A1 Grazioli, Alison
YR 2021
UL http://medrxiv.org/content/early/2021/12/23/2021.12.21.21267733.abstract
AB Although there have been many studies on antibody responses to SARS-CoV-2 in breastmilk, very few have looked at the fate of these in the baby. We carried out a study in 22 mother/baby pairs (mothers who breastfed and who were SARS-CoV-2 vaccinated before or after delivery) looking at mother blood, mother milk, baby blood, baby nose, and baby stool. Breastfed infants only acquired systemic anti-SARS-CoV-2 IgG antibodies if their mothers were vaccinated antepartum. None of the infants had SARS-CoV-2-specific IgA in the blood, but surprisingly, half of the infants in the Antepartum group had high titer SARS-CoV-2-specific IgA in the nose that exceeded titers found in breastmilk. Vaccination antepartum followed by breastfeeding appears to be the best way to provide systemic and local anti-SARS-CoV-2 antibodies for infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMerit Award # I01 BX005469-01Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Maryland Baltimore gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors